

DAFTAR PUSTAKA

- Almon, R.R., Yang, E., Lai, W., Androulakis, I.P., DuBois, D.C., Jusko, W.J., 2008. Circadian variations in rat liver gene expression: relationships to drug actions. *J. Pharmacol. Exp. Ther.* 326, 700–716. doi:10.1124/jpet.108.140186
- Badan Penelitian dan Pengembangan Kesehatan, Departemen Kesehatan RI, 2008. Riset Kesehatan Dasar (Riskesdas), Laporan Nasional 2007.
- Badan Penelitian dan Pengembangan Kesehatan, Kementrian Kesehatan RI, 2013. Penyajian Pokok-Pokok Hasil Riset Kesehatan dasar (RISKESDAS) 2013.
- Blum, C.B., 1994. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. *Am. J. Cardiol.* 73, 3D–11D.
- Cella, L.K., Van Cauter, E., Schoeller, D.A., 1995. Effect of Meal Timing on Diurnal Rhythm of Human Cholesterol Synthesis. *American Journal of Physiology* 269 (5 pt 1), E878-E883
- Dahlan, M. Sopiudin, 2013. Besar Sampel dan Cara Pengambilan Sampel Dalam Penelitian Kedokteran dan Kesehatan, Jakarta, Salemba Medika, hlm. 138-142
- De Giorgi, A., Mallozzi Menegatti, A., Fabbian, F., Portaluppi, F., Manfredini, R., 2013. Circadian rhythms and medical diseases: does it matter when drugs are taken? *Eur. J. Intern. Med.* 24, 698–706. doi:10.1016/j.ejim.2013.03.019
- Grundy, S.M., Cleeman, J.I., Merz, C.N.B., Brewer, H.B., Clark, L.T., Hunninghake, D.B., Pasternak, R.C., Smith, S.C., Stone, N.J., Coordinating Committee of the National Cholesterol Education Program, 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Arterioscler. Thromb. Vasc. Biol.* 24, e149–161. doi:10.1161/01.ATV.0000133317.49796.0E
- Harwood, H.J., Bridge, D.M., Stacpoole, P.W., 1987. In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. *Studies in normal subjects. J. Clin. Invest.* 79, 1125–1132.
- Hatma, R.D., 2011. Lipid profiles among diverse ethnic groups in Indonesia. *Acta Medica Indones.* 43, 4–11.
- Jurevics, H., Hostettler, J., Barrett, C., Morell, P., Toews, A.D., 2000. Diurnal and dietary-induced changes in cholesterol synthesis correlate with levels of mRNA for HMG-CoA reductase. *J. Lipid Res.* 41, 1048–1053.
- Lund, T.M., Torsvik, H., Falch, D., Christophersen, B. jørn, Skårdal, R., Gullestad, L., 2002. Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease. *Am. J. Cardiol.* 90, 784–786. doi:10.1016/S0002-9149(02)02614-0
- Miettinen, T.A., 1980. Diurnal variation of LDL and HDL cholesterol. *Ann. Clin. Res.* 12, 295–298.
- Miida, T., Nakamura, Y., Mezaki, T., Hanyu, O., Maruyama, S., Horikawa, Y., Izawa, S., Yamada, Y., Matsui, H., Okada, M., 2002. LDL-cholesterol and HDL-cholesterol concentrations decrease during the day. *Ann. Clin. Biochem.* 39, 241–249.
- Neese, R.A., Faix, D., Kletke, C., Wu, K., Wang, A.C., Shackleton, C.H., Hellerstein, M.K., 1993. Measurement of endogenous synthesis of plasma cholesterol in rats and humans using MIDA. *Am. J. Physiol. - Endocrinol. Metab.* 264, E136–E147.



- Ohdo, S., Koyanagi, S., Matsunaga, N., Hamdan, A., 2011. Molecular Basis of Chronopharmaceutics. *Journal of Pharmaceutical Sciences*, Vol. 100, 3560-3576. Wiley-Liss, USA.
- Pappu, A.S., Illingworth, D.R., 2002. The effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia. *Atherosclerosis* 165, 137–144. doi:10.1016/S0021-9150(02)00192-2
- Parker, T.S., McNamara, D.J., Brown, C.D., Kolb, R., Ahrens, E.H., Alberts, A.W., Tobert, J., Chen, J., De Schepper, P.J., 1984. Plasma mevalonate as a measure of cholesterol synthesis in man. *J. Clin. Invest.* 74, 795–804. doi:10.1172/JCI111495
- Saito, Y., Yoshida, S., Nakaya, N., Hata, Y., Goto, Y., 1991. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. *Arterioscler. Thromb. J. Vasc. Biol. Am. Heart Assoc.* 11, 816–826.
- Santosa, S., Varady, K.A., AbuMweis, S., Jones, P.J.H., 2007. Physiological and therapeutic factors affecting cholesterol metabolism: Does a reciprocal relationship between cholesterol absorption and synthesis really exist? *Life Sci.* 80, 505–514. doi:10.1016/j.lfs.2006.10.006
- Setiono, L.Y., Suhartono, T., Purwoko, Y., 2012. Dislipidemia Pada Obesitas dan Tidak Obesitas di RSUP DR. Kariadi dan Laboratorium Klinik Swasta di Kota Semarang.
- Silbernagl, S., 2009. *Color Atlas of Pathophysiology*, 2nd edition edition. ed. Thieme, Stuttgart; New York.
- Srinivasa, R.K., Prasad, T., Mohanta, G.P., Manna, P.K., 2011. An Overview of Statins as Hypolipidemic Drugs. *IJPSDR* July-Sept. 2011 Vol 3, 178–183.
- Smith, D.G., 2007. Epidemiology of dyslipidemia and economic burden on the healthcare system. *Am. J. Manag. Care* 13 Suppl 3, S68–71.
- Sukumaran, S., Almon, R.R., DuBois, D.C., Jusko, W.J., 2010. Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. *Adv. Drug Deliv. Rev.* 62, 904–917. doi:10.1016/j.addr.2010.05.009
- Talbert, R.L., Posey, L.M., 2014. *Pharmacotherapy A Pathophysiologic Approach* 9/E, 9 edition. ed. McGraw-Hill Medical, New York.
- Tilvis, R., Kovanen, P.T., Miettinen, T.A., 1982. Metabolism of squalene in human fat cells. Demonstration of a two-pool system. *J. Biol. Chem.* 257, 10300–10305.
- Van der Wulp, M.Y.M., Verkade, H.J., Groen, A.K., 2013. Regulation of cholesterol homeostasis. *Mol. Cell. Endocrinol., Nuclear Receptors, Bile Acids and Cholesterol Homeostasis* 368, 1–16. doi:10.1016/j.mce.2012.06.007
- Wallace, A., Chinn, D., Rubin, G., 2003. Taking simvastatin in the morning compared with in the evening: randomised controlled trial. *BMJ* 327, 788. doi:10.1136/bmj.327.7418.788
- Wells, B., DiPiro, J., Schwinghammer, T., DiPiro, C., 2008. *Pharmacotherapy Handbook*, Seventh Edition, 7 edition. ed. McGraw-Hill Medical, New York.
- Wright, D.F.B., Pavan Kumar, V.V., Al-Sallami, H.S., Duffull, S.B., 2011. The influence of dosing time, variable compliance and circadian low-density lipoprotein production on the effect of simvastatin: simulations from a pharmacokinetic-pharmacodynamic model. *Basic Clin. Pharmacol. Toxicol.* 109, 494–498. doi:10.1111/j.1742-7843.2011.00757.x